2018 Q3 Form 10-Q Financial Statement

#000156459018028291 Filed on November 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q4 2017 Q3
Revenue $45.89M $52.03M $42.31M
YoY Change 8.44% 46.56% 31.2%
Cost Of Revenue $17.34M $23.50M $17.67M
YoY Change -1.87% 103.46% 84.52%
Gross Profit $28.55M $28.53M $24.64M
YoY Change 15.85% 19.12% 8.68%
Gross Profit Margin 62.22% 54.84% 58.24%
Selling, General & Admin $13.83M $14.54M $14.10M
YoY Change -1.89% -7.21% 5.71%
% of Gross Profit 48.44% 50.96% 57.2%
Research & Development $3.860M $3.830M $3.228M
YoY Change 19.58% 216.53% 1.0%
% of Gross Profit 13.52% 13.42% 13.1%
Depreciation & Amortization $1.842M $1.490M $1.698M
YoY Change 8.48% 0.0% 20.08%
% of Gross Profit 6.45% 5.22% 6.89%
Operating Expenses $17.69M $18.37M $17.33M
YoY Change 2.1% 8.83% 4.8%
Operating Profit $10.86M $10.16M $7.319M
YoY Change 48.34% 43.66% 19.12%
Interest Expense -$380.0K
YoY Change
% of Operating Profit -3.5%
Other Income/Expense, Net $510.0K $118.0K $113.0K
YoY Change 351.33% 28.26% -77.31%
Pretax Income $11.37M $10.28M $7.432M
YoY Change 52.95% 43.46% 11.89%
Income Tax $3.271M $2.963M $1.669M
% Of Pretax Income 28.78% 28.83% 22.46%
Net Earnings $8.096M $7.316M $5.763M
YoY Change 40.48% 1.67% -7.67%
Net Earnings / Revenue 17.64% 14.06% 13.62%
Basic Earnings Per Share $0.13 $0.12 $0.10
Diluted Earnings Per Share $0.13 $0.12 $0.09
COMMON SHARES
Basic Shares Outstanding 61.21M 60.65M shares 60.09M shares
Diluted Shares Outstanding 62.61M 62.17M shares

Balance Sheet

Concept 2018 Q3 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $150.3M $154.1M $160.1M
YoY Change -6.12% 29.39% 34.2%
Cash & Equivalents $78.15M $71.03M $76.77M
Short-Term Investments $72.20M $83.00M $83.40M
Other Short-Term Assets $4.400M $2.486M $1.206M
YoY Change 264.84% 16.01% 82.73%
Inventory $19.90M $19.34M $16.86M
Prepaid Expenses $1.658M $1.189M
Receivables $33.30M $42.52M $28.10M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $207.9M $221.9M $209.3M
YoY Change -0.69% 41.85% 38.89%
LONG-TERM ASSETS
Property, Plant & Equipment $24.40M $21.37M $21.50M
YoY Change 13.51% 6.68% 7.11%
Goodwill $20.08M $20.26M
YoY Change 6.86% 5.27%
Intangibles $6.053M $8.223M $8.972M
YoY Change -32.53% -20.45% -19.93%
Long-Term Investments $41.80M $20.70M $18.30M
YoY Change 128.42%
Other Assets $4.600M $3.928M $3.909M
YoY Change 17.68% 68.51% 68.35%
Total Long-Term Assets $96.40M $74.30M $72.92M
YoY Change 32.19% 44.28% 38.01%
TOTAL ASSETS
Total Short-Term Assets $207.9M $221.9M $209.3M
Total Long-Term Assets $96.40M $74.30M $72.92M
Total Assets $304.3M $296.2M $282.3M
YoY Change 7.81% 42.45% 38.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.100M $10.23M $9.624M
YoY Change -15.84% 120.76% 117.64%
Accrued Expenses $10.30M $20.70M $15.81M
YoY Change -34.86% 82.91% 64.41%
Deferred Revenue $1.314M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.40M $32.24M $26.62M
YoY Change -19.62% 85.96% 21.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.600M $3.932M $3.928M
YoY Change 17.11% 70.66% 71.6%
Total Long-Term Liabilities $4.600M $3.932M $3.928M
YoY Change 17.11% 70.66% 71.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.40M $32.24M $26.62M
Total Long-Term Liabilities $4.600M $3.932M $3.928M
Total Liabilities $27.60M $36.17M $30.55M
YoY Change -9.66% 84.17% 26.04%
SHAREHOLDERS EQUITY
Retained Earnings -$119.5M -$126.8M
YoY Change -20.57% -19.55%
Common Stock $387.9M $386.0M
YoY Change 10.67% 11.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $276.8M $258.1M $249.5M
YoY Change
Total Liabilities & Shareholders Equity $304.3M $296.2M $282.3M
YoY Change 7.81% 42.45% 38.66%

Cashflow Statement

Concept 2018 Q3 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income $8.096M $7.316M $5.763M
YoY Change 40.48% 1.67% -7.67%
Depreciation, Depletion And Amortization $1.842M $1.490M $1.698M
YoY Change 8.48% 0.0% 20.08%
Cash From Operating Activities $10.88M -$2.200M $8.660M
YoY Change 25.64% 279.31% 2.61%
INVESTING ACTIVITIES
Capital Expenditures $1.454M -$880.0K $1.895M
YoY Change -23.27% 4.76% 142.02%
Acquisitions
YoY Change
Other Investing Activities -$3.560M -$2.460M -$45.91M
YoY Change -92.25% -33.69%
Cash From Investing Activities -$5.010M -$3.320M -$47.81M
YoY Change -89.52% -27.19% 6029.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 470.0K 270.0K 10.36M
YoY Change -95.46% -83.33% 3137.5%
NET CHANGE
Cash From Operating Activities 10.88M -2.200M 8.660M
Cash From Investing Activities -5.010M -3.320M -47.81M
Cash From Financing Activities 470.0K 270.0K 10.36M
Net Change In Cash 6.340M -5.250M -28.79M
YoY Change -122.02% 49.15% -460.78%
FREE CASH FLOW
Cash From Operating Activities $10.88M -$2.200M $8.660M
Capital Expenditures $1.454M -$880.0K $1.895M
Free Cash Flow $9.426M -$1.320M $6.765M
YoY Change 39.33% -607.69% -11.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60569000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1840000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
83028000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
42521000
CY2017Q4 us-gaap Inventory Net
InventoryNet
19343000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1658000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2486000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
221905000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10228000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21372000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1951000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1314000
CY2017Q4 us-gaap Assets
Assets
296201000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119510000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20695000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32237000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3932000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
387931000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10340000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
258081000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-425000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
21541000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
296201000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
471000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60662000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60662000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115036000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21777000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
12500000
us-gaap Operating Expenses
OperatingExpenses
40354000
us-gaap Operating Income Loss
OperatingIncomeLoss
30077000
us-gaap Profit Loss
ProfitLoss
23632000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
676000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
30753000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7121000
us-gaap Net Income Loss
NetIncomeLoss
23632000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58511000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4882000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-300000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
28214000
us-gaap Share Based Compensation
ShareBasedCompensation
5213000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4589000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
246000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7706000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4886000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1616000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4593000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-212000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-300000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4193000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
30361000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
132177000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
42613000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3462000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-93026000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
31402000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1234000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30168000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1317000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31180000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
78610000
us-gaap Income Taxes Paid
IncomeTaxesPaid
4317000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
437000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-352000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Use of Estimates</font>.<font style="font-style:normal;"> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, and performance-based compensation expense, among others. These estimates and assumptions are based on management&#8217;s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.</font></p></div>
us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div> <p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:3.12%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:6.25%;text-indent:3.12%;"><font style="text-decoration:underline;">Product sales</font>. <font style="font-style:normal;">Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that reflects the consideration we are entitled to, net of allowances for any discounts or rebates.&nbsp;&nbsp; </font></p> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:3.12%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p> <p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:3.12%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net revenues recorded for sales of the OraQuick<sup style="font-size:85%; vertical-align:top">&#174;</sup> In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks.&nbsp;&nbsp;The allowance for expected returns is an estimate established by management, based upon currently available information, and is adjusted to reflect known changes in the factors that impact this estimate.&nbsp;&nbsp;Other customer allowances are at contractual rates and are recorded as a reduction of gross revenue when recognized in our consolidated statements of operations.</p> <p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:3.12%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:3.12%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.</p> <p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:3.12%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<div> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:3.12%;"><font style="text-decoration:underline;">Arrangements with multiple-performance obligations</font><font style="font-style:normal;">.&nbsp;&nbsp;In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or services is separately identifiable from other promises in the contract.&nbsp;&nbsp;The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price.&nbsp;&nbsp;The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.&nbsp;&nbsp;The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services.&nbsp;&nbsp;&nbsp;&nbsp;</font></p></div>
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:3.12%;"><font style="text-decoration:underline;">Deferred Revenue</font><font style="font-style:normal;">.&nbsp;&nbsp;</font><font style="font-style:normal;">We record deferred revenue when funds are received prior to the recognition of the associated revenue.&nbsp;&nbsp;Deferred revenue as of September&#160;30, 2018 and December&#160;31, 2017 includes customer prepayments of $1,882 and $1,045, respectively.&nbsp;&nbsp;Deferred revenue as of September&#160;30, 2018 and December&#160;31, 2017 also includes $1,224 and $269, respectively, associated with a long-term contract that has variable pricing based on volume.&nbsp;&nbsp;The average price over the life of the contract was determined and revenue is recognized at that rate.</font></p></div>
CY2018Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
553000
CY2018Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
113980000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
103718000
CY2018Q3 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
5180000
CY2017Q4 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
3514000
CY2018Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7822000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8845000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
42109000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
39379000
CY2018Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
20309000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
18692000
CY2018Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6053000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8223000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2009000
us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
-161000
CY2018Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1398000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2018Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
114885000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
104271000
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
199000
CY2017Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2082000
CY2018Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-375000
CY2017Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-638000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-30000
CY2015Q2 osur Maximum Contract Revenue From Clinical And Regulatory Activities
MaximumContractRevenueFromClinicalAndRegulatoryActivities
10400000
CY2015Q2 osur Amended Contract Expiration Period
AmendedContractExpirationPeriod
2019-12-31
CY2015Q2 osur Initial Contract Revenue From Clinical And Regulatory Activities
InitialContractRevenueFromClinicalAndRegulatoryActivities
1800000
CY2015Q2 osur Remaining Contract Revenue From Clinical And Regulatory Activities
RemainingContractRevenueFromClinicalAndRegulatoryActivities
8600000
CY2017Q3 osur Additional Contract Revenue From Clinical And Regulatory Activities
AdditionalContractRevenueFromClinicalAndRegulatoryActivities
1330000
osur Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
1260000
CY2016Q3 osur Maximum Contract Revenue From Clinical And Regulatory Activities
MaximumContractRevenueFromClinicalAndRegulatoryActivities
16600000
CY2016Q3 osur Contract Expiration Period
ContractExpirationPeriod
P6Y
CY2016Q3 osur Initial Contract Revenue From Clinical And Regulatory Activities
InitialContractRevenueFromClinicalAndRegulatoryActivities
7000000
CY2016Q3 osur Remaining Contract Revenue From Clinical And Regulatory Activities
RemainingContractRevenueFromClinicalAndRegulatoryActivities
9600000
CY2017Q2 osur Additional Contract Revenue From Clinical And Regulatory Activities
AdditionalContractRevenueFromClinicalAndRegulatoryActivities
2600000
us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.
CY2017 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
217000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6629000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9265000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1171000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1064000
CY2018Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
107000
CY2017Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
845000
CY2017Q4 us-gaap Taxes Payable Current And Noncurrent
TaxesPayableCurrentAndNoncurrent
6469000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2343000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1480000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2058000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1256000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
11810000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
9787000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
905000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
553000
CY2015Q2 osur Contract Expiration Period
ContractExpirationPeriod
P3Y
CY2015Q2 osur Contract Expiration Period Month And Year
ContractExpirationPeriodMonthAndYear
2018-10
CY2015Q3 osur Additional Contract Revenue From Clinical And Regulatory Activities
AdditionalContractRevenueFromClinicalAndRegulatoryActivities
7200000
CY2018Q3 osur Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
782000
osur Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
2581000
CY2017Q3 osur Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
386000
us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
181000
CY2018Q3 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
CY2018Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1842000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3052000
CY2018Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
10000000
us-gaap Line Of Credit Facility Collateral
LineOfCreditFacilityCollateral
Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.
CY2018Q3 us-gaap Line Of Credit
LineOfCredit
0
CY2017Q4 us-gaap Line Of Credit
LineOfCredit
0
us-gaap Line Of Credit Facility Unused Capacity Commitment Fee Percentage
LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
0.00375
us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2019-09-30
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2008Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
25000000
CY2017Q3 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2017Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1698000
CY2018Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1454000
CY2017Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1895000

Files In Submission

Name View Source Status
0001564590-18-028291-index-headers.html Edgar Link pending
0001564590-18-028291-index.html Edgar Link pending
0001564590-18-028291.txt Edgar Link pending
0001564590-18-028291-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
osur-10q_20180930.htm Edgar Link pending
osur-20180930.xml Edgar Link completed
osur-20180930.xsd Edgar Link pending
osur-20180930_cal.xml Edgar Link unprocessable
osur-20180930_def.xml Edgar Link unprocessable
osur-20180930_lab.xml Edgar Link unprocessable
osur-20180930_pre.xml Edgar Link unprocessable
osur-ex311_7.htm Edgar Link pending
osur-ex312_6.htm Edgar Link pending
osur-ex321_9.htm Edgar Link pending
osur-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending